Nicox Provides Video Update on Latest Developments

FOR INFORMATION

Nicox Provides Video Update on Latest Developments

March 2, 2021 – release at 7:30 am CET Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided a brief video update on latest developments.

Michele Garufi, Chairman and Chief Executive Officer of Nicox, discusses recent developments and planned upcoming milestones, including expected top-line results from two Phase 3 trials of lead product candidate NCX 470 for the treatment of glaucoma, as well as Phase 2b top-line results with NCX 4251 for the treatment of blepharitis and highlights the differentiation of these two product candidates from existing therapies.

To access the video, click here. About Nicox Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.  Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma.  The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis.  Nicox generates revenue from VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets. 

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com. Analyst coverage  

Bryan, Garnier & Co               Victor Floc’h          Paris, France
Cantor Fitzgerald                    Louise Chen          New York, U.S.